Dr. Richard Isaacson joined CNN International following the FDA’s full approval of Leqembi, one of the first medications shown to slow the progression of early Alzheimer’s disease. During the interview, he described the approval as the beginning of a new era in Alzheimer’s treatment, emphasizing that while the therapy is not a cure, it offers meaningful hope by slowing disease progression when used in the earliest stages.

Dr. Isaacson also discussed the importance of identifying the right patients through biomarker testing, the need for specialized infusion centers and ongoing MRI monitoring, and the challenges of making these breakthrough treatments broadly accessible. He emphasized that medications like Leqembi work best as part of a comprehensive, personalized approach that includes early detection, precision medicine, and strategies to support long-term brain health.

Watch the full CNN International interview to learn how new Alzheimer’s therapies are changing the future of treatment and what patients and families should know about this important milestone.